The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | Recent approvals and updates impacting myeloma treatment in the UK
Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, comments on the recent updates to the treatment of multiple myeloma (MM) in the UK, highlighting the approvals of the bispecific antibodies teclistamab and elranatamab in the fourth line setting. Prof. Jackson emphasizes the importance of community physicians understanding the potential benefits and challenges of these novel agents, including their administration via subcutaneous injection, associated side effects, and longer-term risks of infection. Selinexor has also been approved in combination with bortezomib and dexamethasone in the second line and beyond, further expanding treatment options for patients. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
I think there have been obviously the approvals of the bispecifics, teclistamab and elranatamab at the fourth line setting and beyond. I think there was a very important battle to be had because initially there was going to be some significant restrictions put on that approval. And fortunately, Myeloma UK have really fought hard to make those treatments available for everyone and that’s been a big battle and these treatments are really impressive...
I think there have been obviously the approvals of the bispecifics, teclistamab and elranatamab at the fourth line setting and beyond. I think there was a very important battle to be had because initially there was going to be some significant restrictions put on that approval. And fortunately, Myeloma UK have really fought hard to make those treatments available for everyone and that’s been a big battle and these treatments are really impressive. They’ve got high response rates, they are single agent treatments, they have to be given subcutaneously obviously, but I think that’s going to change the outcomes for many many myeloma patients.
Of course it’s a new therapy and not everyone has used these drugs before so each centre, each myeloma treating team has got to work out how they use them. We know that the first two or three injections are associated with side effects such as CRS and ICANS, and each region has got to work out the strategy for delivering these safely. The other issue around these agents is longer term they’re associated with higher risks of infection and again I think each region and each MDT has to have an approach to mitigating that infection risk in patients on those therapies.
We’ve also had selinexor approved with Velcade and dexamethasone at second, third and fourth line, which just gives us another option in patients who may not be eligible for other therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Johnson & Johnson, Amgen, Sanofi, Bristol Myers Squibb, Takeda, Pfizer, Menarini: Honoraria for advisory boards/speaking; Onyx, Bristol Myers Squibb, Takeda: Research Funding.
